Floatz logo

Capecitabine

Radiation Toxicity

National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Radiation Toxicity cohort.

Asset / SponsorPhaseRating
FILGRASTIM
IRCCS San Raffaele
Phase 3BB
Amifostine
Alliance for Clinical Trials in Oncology
Phase 3BB
Sra-333
Wake Forest University Health Sciences
Phase 3BB
ETOPOSIDE
Sun Yat-sen University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 3BB

View all 26 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →